Eligible patients were randomized to eribulin mesylate @ mg/m ( @ ) on day @ with erlotinib @ mg on days @-@ ( @-day regimen ) or eribulin mesylate @ mg/m ( @ ) on days @ and @ with erlotinib @ mg on days @-@ ( @-day regimen ) .